Daratumumab subcutaneous injection (Darzalex®) is accepted for restricted use within NHSScotland for treatment of relapsed and refractory multiple myeloma

Treatment as monotherapy is restricted to use as a fourth-line option for adults with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on last therapy.

Source:

Scottish Medicines Consortium